Conversion from conventional to atypical neuroleptics - Recommendations for inpatient and outpatient treatment;Umstellung von typischen auf atypische neuroleptika: Richtlinien zur ambulanten und stationaren behandlung

Nervenarzt

Volumn 71, Issue 11, 2000, Pages 859-875

  Lambert, M ^a   Moritz, S ^a   Haasen, C ^a   Naber, D ^a  

^a UNIVERSITY OF HAMBURG   (Germany)

Author keywords

Atypical antipsychotics; Conventional antipsychotics; Conversion; Schizophrenia

Indexed keywords

AMISULPRIDE; ANTIARRHYTHMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOZAPINE; FLUOXETINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PHENOTHIAZINE; QUETIAPINE; RISPERIDONE; TRICYCLIC ANTIDEPRESSANT AGENT; ZIPRASIDONE; ZOTEPINE;

DRUG EFFECT; HOSPITAL PATIENT; HUMAN; OUTPATIENT CARE; PRACTICE GUIDELINE; REVIEW; SCHIZOPHRENIA; TREATMENT PLANNING;

AMBULATORY CARE; ANTIPSYCHOTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; HUMANS; PATIENT ADMISSION; PRACTICE GUIDELINES; SCHIZOPHRENIA;

EID: 0033742661     PISSN: 00282804     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001150050677     Document Type: Review

References (53)

1. Antipsychotic-induced weight gain: A comprehensive research symthesis
2. Multiple fixed dose of 'Seroquel' (Quetiapine) in patients with acute exacerbation of schizophrenia: A comparison with Haloperidol and Placebo
3. Cytochromes and psychotropic drug interactions
4. Olanzapine-induced neutropenia after clozapine-induced neutropenia
5. Clozapine and risperidone in chronic schizophrenia: Effects on symptoms, parkinsonian side effects, and neuroendocrine response
6. Changing antipsychotic medication: Guidelines on the transition to treatment with risperidone. The Consensus Study Group on Risperidone Dosing
7. Withdrawal from neuroleptic drugs
8. 'Seroquel' (quetiapine): Preclinical and clinical findings of a new atypical antipsychotic
9. A Canadian multicenter placebo controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients
10. Persistence of haloperidol in the brain
11. Amisulpride. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of schizophrenia
12. Safety of amisulpride: A review of 11 clinical studies
13. Switching from depot antipsychotics to risperidone: Results of a study of chronic schizophrenia. The Schizophrenia Treatment and Assessment Group
14. Genetic determinants of drug-induced agranulocytosis: Potential risk of olanzapine?
15. Olanazpine for patients with treatment-resistant schizophrenia: A naturalistic case-series outcome study
16. An exploratory Haloperidol-controlled dose-finding study of Ziprasidone in hospitalized patients with schizophrenia or schizoaffective disorder
17. Agranulocytosis and significant leucopenia with neuroleptic drugs: Results from the AMUP program
18. Convulsive seizures in schizophrenic patients induced by zotepine administration
19. Zotepin in der behandlung akuter, hospitalisierter schizophrener psychosen
20. Discontinuing antipsychotic therapy: A practical guide
21. A comparison of bd and tid dose regimes of quetiapine (Seroquel) in the treatment of schizophrenia
22. Observations on switching patients with schizophrenia to risperidone treatment. Risperidone Switching Study Group
23. Persistence of haloperidol in human brain tissue
24. Olanzapin - Ein atypisches antipsychotikum in der behandlung schizophrener erkrankungen
25. Amisulprid - Ein atypisches antipsychotikum in der behandlung schizophrener erkrankungen
26. Amisulpride in the medium-term treatment of the negative symptoms of schizophrenia
27. The role of cholinergic supersensitivity in the medical symptoms associated with withdrawal of antipsychotic drugs
28. Risperidone in the treatment of schizophrenia
29. Switching antipsychotic therapies
30. The Expert Consensus Guideline Series: Treatment of schizophrenia 1999
31. A study of withdrawal of chlorpromazine or trifluoperazine in chronic schizophrenia
32. Refractory Schizophrenia
33. Implications of brain imaging for the management of Schizophrenia
34. Improvement of some schizophrenic deficit symptoms with low doses of amisulpride
35. Zotepine. A review of ist pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of schizophrenia
36. Relapse in chronic schizophrenics following abrupt withdrawal of tranquillising medication
37. Use of high-dose olanzapine in refractory psychosis
38. Neuroleptic Withdrawal when switching from typical to atypical antipsychotics: Preclinical findings
39. Persistence of plasma neuroleptic levels aufter drug discontinuation
40. Switching from typical to atypical neuroleptics
41. Switching antipsychotic medications
42. Long-term considerations after switching antipsychotics
43. A depot neuroleptic withdrawal study: A controlled study of the clinical effects of the withdrawal of depot fluphenazine decanoate and depot flupentixol decanoate in chronic schizophrenic patients